Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

regeneron headquarters

Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

- PMLiVE

Artificial Intelligence:  How to approach the ethical cost of innovation

In a rapidly evolving industry, staying ahead means embracing new tools thoughtfully. We're setting the gold standard by ethically leveraging AI to drive innovation while ensuring patient trust and regulatory...

Mednet

- PMLiVE

How can we navigate the tension between scientific rigor and emotional resonance in brand storytelling?

In her first Ask Alex article of the year, Scientific Director, Dr Alexandra Loveday explores the ways our expert writers combine rigorous scientific data with empathetic and engaging content to...

Mednet

- PMLiVE

Is modular content the secret to smarter medical communications?

In her latest Ask Alex article, Principal Medical Writer, Dr Alexandra Loveday explores modular content and whether it holds the secret to smarter and more effective medical communications. As healthcare...

Mednet

- PMLiVE

J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition

The deal gives the company access to a range of central nervous system disorder drugs

- PMLiVE

Eli Lilly to acquire Scorpion’s solid tumour programme in deal worth $2.5bn

STX-478 is in phase 1/2 development for breast cancer and other advanced solid tumours

- PMLiVE

Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

GSK to expand gastrointestinal cancer pipeline with $1bn IDRx acquisition

The deal includes a TKI in development for gastrointestinal stromal tumours

- PMLiVE

Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma

Approximately 32,000 people are diagnosed with the haematological malignancy in the US every year

Bayer symbol

Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

- PMLiVE

Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links